103 related articles for article (PubMed ID: 7981894)
1. Expression of Kirsten-ras p21 in gastric cancer correlates with tumor progression and is prognostic.
Motojima K; Furui J; Kohara N; Izawa K; Kanematsu T; Shiku H
Diagn Mol Pathol; 1994 Sep; 3(3):184-91. PubMed ID: 7981894
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical analysis of ras oncogene p21 product in human gastric carcinomas and their adjacent mucosas.
Carneiro F; David L; Sunkel C; Lopes C; Sobrinho-Simões M
Pathol Res Pract; 1992 Apr; 188(3):263-72. PubMed ID: 1625989
[TBL] [Abstract][Full Text] [Related]
3. Ha-ras oncogene product in human gastric carcinoma: correlation with invasiveness, metastasis or prognosis.
Tahara E; Yasui W; Taniyama K; Ochiai A; Yamamoto T; Nakajo S; Yamamoto M
Jpn J Cancer Res; 1986 Jun; 77(6):517-22. PubMed ID: 3089984
[TBL] [Abstract][Full Text] [Related]
4. erbB-2 expression in well-differentiated adenocarcinoma of the stomach predicts shorter survival after curative resection.
Motojima K; Furui J; Kohara N; Izawa K; Kanematsu T; Shiku H
Surgery; 1994 Mar; 115(3):349-54. PubMed ID: 7907434
[TBL] [Abstract][Full Text] [Related]
5. P21 protein expression and ras-oncogene mutations in gastric carcinoma: correlation with clinical data.
Kasper HU; Schneider-Stock R; Mellin W; Roessner A
Int J Oncol; 1998 Jan; 12(1):69-74. PubMed ID: 9454888
[TBL] [Abstract][Full Text] [Related]
6. Expression of p53 protein in gastric carcinomas is not independently prognostic.
Motojima K; Furui J; Kohara N; Ito T; Kanematsu T
Surgery; 1994 Nov; 116(5):890-5. PubMed ID: 7940194
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer.
Miyamoto H; Harada M; Isobe H; Akita HD; Haneda H; Yamaguchi E; Kuzumaki N; Kawakami Y
Cancer Res; 1991 Dec; 51(23 Pt 1):6346-50. PubMed ID: 1657384
[TBL] [Abstract][Full Text] [Related]
8. Correlation of COX-2 and K-ras expression to clinical outcome in gastric cancer.
Li M; Liu W; Zhu YF; Chen YL; Zhang BZ; Wang R
Acta Oncol; 2006; 45(8):1115-9. PubMed ID: 17118848
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical study of oncogene product ras p21, c-myc and growth factor EGF in breast carcinomas.
Mizukami Y; Nonomura A; Noguchi M; Taniya T; Koyasaki N; Saito Y; Hashimoto T; Matsubara F; Yanaihara N
Anticancer Res; 1991; 11(4):1485-94. PubMed ID: 1660689
[TBL] [Abstract][Full Text] [Related]
10. Interaction between transforming growth factor-alpha and c-Ha-ras p21 in progression of human gastric carcinoma.
Yamamoto T; Hattori T; Tahara E
Pathol Res Pract; 1988 Nov; 183(6):663-9. PubMed ID: 3065747
[TBL] [Abstract][Full Text] [Related]
11. DNA aneuploidy and high proliferative activity but not K-ras-2 mutations as independent predictors of clinical outcome in operable gastric carcinoma: results of a 5-year Gruppo Oncologico dell'Italia Meridonale (GDIM) prospective study.
Russo A; Bazan V; Migliavacca M; Tubiolo C; Macaluso M; Zanna I; Corsale S; Latteri F; Valerio MR; Pantuso G; Morello V; Dardanoni G; Latteri MA; Colucci G; Tomasino RM; Gebbia N
Cancer; 2001 Jul; 92(2):294-302. PubMed ID: 11466682
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous expression of the ras p21 and p53 proteins in human endometrial carcinomas.
Miturski R; Semczuk A; Jakowicki J
Acta Histochem; 1996 Nov; 98(4):411-8. PubMed ID: 8960305
[TBL] [Abstract][Full Text] [Related]
13. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
[TBL] [Abstract][Full Text] [Related]
14. Enhanced expression of c-Ha-ras p21 in human stomach adenocarcinomas defined by immunoassays using monoclonal antibodies and in situ hybridization.
Ohuchi N; Hand PH; Merlo G; Fujita J; Mariani-Costantini R; Thor A; Nose M; Callahan R; Schlom J
Cancer Res; 1987 Mar; 47(5):1413-20. PubMed ID: 2434216
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer.
Fujino M; Dosaka-Akita H; Harada M; Hiroumi H; Kinoshita I; Akie K; Kawakami Y
Cancer; 1995 Dec; 76(12):2457-63. PubMed ID: 8625071
[TBL] [Abstract][Full Text] [Related]
16. The prognostic relevance of fascin expression in human gastric carcinoma.
Hashimoto Y; Shimada Y; Kawamura J; Yamasaki S; Imamura M
Oncology; 2004; 67(3-4):262-70. PubMed ID: 15557788
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of c-H-ras p21 is correlated with vascular endothelial growth factor expression and neovascularization in advanced gastric carcinoma.
Kim YB; Han JY; Kim TS; Kim PS; Chu YC
J Gastroenterol Hepatol; 2000 Dec; 15(12):1393-9. PubMed ID: 11197049
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of p21 and p53 expression in gastric cancer.
Seo YH; Joo YE; Choi SK; Rew JS; Park CS; Kim SJ
Korean J Intern Med; 2003 Jun; 18(2):98-103. PubMed ID: 12872447
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical detection of H-ras protooncoprotein p21 indicates favorable prognosis in node-negative breast cancer patients.
Göhring UJ; Schöndorf T; Kiecker VR; Becker M; Kurbacher C; Scharl A
Tumour Biol; 1999; 20(4):173-83. PubMed ID: 10393527
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
